2017
DOI: 10.1016/s1470-2045(17)30279-6
|View full text |Cite
|
Sign up to set email alerts
|

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Abstract: Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. Methods The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

15
459
3
11

Year Published

2017
2017
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 508 publications
(488 citation statements)
references
References 32 publications
15
459
3
11
Order By: Relevance
“…On the basis of the results of the OCEANS trial, bevacizumab has been approved in Europe in combination with carboplatin-gemcitabine chemotherapy for the treatment of platinum-sensitive patients. 25 Recently, 2 chemotherapy schedules (carboplatin and gemcitabine vs carboplatin and PLD) in combination with bevacizumab have been compared in the ENGOT-OV18/AGO-OVAR 2.21 trial. The overall response rate was significantly improved in the bevacizumab-containing arm (78.5% vs 57.4%), and PFS was longer in comparison with the placebo group (12.4 vs 8.4 months).…”
Section: Patients Who Are Candidates For Platinum Rechallengementioning
confidence: 99%
“…On the basis of the results of the OCEANS trial, bevacizumab has been approved in Europe in combination with carboplatin-gemcitabine chemotherapy for the treatment of platinum-sensitive patients. 25 Recently, 2 chemotherapy schedules (carboplatin and gemcitabine vs carboplatin and PLD) in combination with bevacizumab have been compared in the ENGOT-OV18/AGO-OVAR 2.21 trial. The overall response rate was significantly improved in the bevacizumab-containing arm (78.5% vs 57.4%), and PFS was longer in comparison with the placebo group (12.4 vs 8.4 months).…”
Section: Patients Who Are Candidates For Platinum Rechallengementioning
confidence: 99%
“…3 For patients with platinum-sensitive recurrent ovarian carcinoma, maintenance treatment with targeted agents has resulted in greater prolongation of progression-free survival than without this treatment. 4, 5, 6, 7, 8, 9 However, clinical benefit is typically transient, hence the pursuit continues for new therapies and tools to identify patients who might benefit most from these therapies, as well as to identify the optimal therapeutic strategy.…”
Section: Introductionmentioning
confidence: 99%
“…More recently, there has been extensive clinical evaluation of targeted strategies, including antiangiogenic agents and polyADP ribose polymerase (PARP) inhibitors. Among the antiangiogenic therapies, bevacizumab—a monoclonal antibody targeting vascular endothelial growth factor (VEGF)—is the most broadly studied and is an approved therapy across the ovarian cancer treatment spectrum, based on results of phase III trials in the front‐line, platinum‐sensitive recurrent and platinum‐resistant recurrent settings . Other antiangiogenic approaches explored in ovarian cancer include tyrosine kinase inhibitors (TKIs), such as pazopanib and nintedanib, a triple angiokinase inhibitor that targets VEGF receptors 1–3, platelet‐derived growth factor receptor α and β, and fibroblast growth factor receptors 1–3 .…”
Section: Introductionmentioning
confidence: 99%